- Home
- EDIT vs DYOR Comparison
EDIT vs DYOR Comparison
Compare EDIT & DYOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | DYOR |
|---|---|---|
| Founded | 2013 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.8M | 227.7M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EDIT | DYOR |
|---|---|---|
| Price | $2.15 | $9.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 67.9K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,383,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $9.87 |
| 52 Week High | $4.54 | $9.96 |
Technical Indicators
Market Signals| Indicator | EDIT | DYOR |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | N/A |
| Support Level | $1.95 | N/A |
| Resistance Level | $2.61 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 28.03 | 0.00 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About DYOR Insight Digital Partners II Class A Ordinary Shares
Insight Digital Partners II is a blank check company.